[This review was originally posted at the Nieman Journalism Lab Glucophage Dosage, on June 22, 2012.]
Microsoft's unknown but intriguing tablet: Yet another company made its jump into the tablet market this week, but this was a more formidable competitor than most: Microsoft unveiled its new Surface tablet PC with precious little information, though the keyboard-cover and Windows 8 operating system got some critics' attention. Reaction from analysts was generally mixed (you can see a good variety at Engadget and the Guardian) — many were intrigued and encouraged by what they saw so far, but wanted to know more before they formed a verdict.
The big question for many observers was whether Surface might finally present a legitimate competitor for the iPad. Reuters talked to experts who said it's too soon to tell (especially since we don't know its price yet), and The New York Times' David Pogue argued that Microsoft has an uphill battle to fight, particularly because of how far behind Apple it's starting. Order Glucophage online c.o.d, The Times' Sam Grobart, however, said Microsoft may be gunning more for the ultra-light notebook computing market than the touch-screen tablet market.
Mat Honan of Gizmodo said Surface's keyboard will be the key to challenging the iPad and Macbook Air's dominance in those areas, and Dutch entrepreneur Max Huijgen asserted that the keyboard finally moves tablets from consumption to creation devices, Glucophage Dosage. The Verge's Joshua Topolsky said Surface could fit perfectly between the iPad and the laptop, but it'll depend on price and how many developers they can get to create apps for it.
Several others noted that this week's announcement marked a significant shift for Microsoft — from software developer to hardware producer. Microsoft has ventured into hardware before (most notably with its mp3 player Zune), but as All Things D's Ina Fried pointed out, buy generic Glucophage, this is a much more important venture. Slate's Farhad Manjoo argued that the Surface seems to be a much more thought-out venture into hardware than the Zune. He and Dan Frommer Glucophage Dosage, of SplatF were excited that Microsoft is finally taking quality hardware into its own hands, as Frommer said: "it sure looks like a better strategy for Microsoft than only trusting the Samsungs of the world to design great Windows tablets, and only trying to generate mobile revenue from Windows sales."
Meanwhile, the Columbia Journalism Review's Ryan Chittum took the opportunity to chastise the tech press for its fawning coverage of product announcements, saying they're acting more like an infomercial audience than journalists.
Blogging, big ideas, and 'self-plagiarism': One of nonfiction writing's young stars was discovered to be repeatedly reusing his own work this week, raising some questions about the relationship between journalism, Glucophage blogs, blogging, and trading in "big ideas." Jonah Lehrer, who was recently hired by The New Yorker, was discovered to have borrowed much of the material for his first several New Yorker blog posts from earlier pieces. Jim Romenesko first uncovered the repetition in one post, and it was quickly found in each of his others, as New York magazine documented.
Edward Champion of Reluctant Habits soon found several re-used passages in Lehrer's most recent book, is Glucophage addictive, and more serious issues cropped up as well: Romenesko and Poynter's Andrew Beaujon noted cases in which Lehrer had made it sound like he had gathered information directly when they had in fact come from secondhand sources. All of Lehrer's New Yorker posts now contain editor's notes, and Lehrer has apologized. While his editor at The New Yorker said he "understands he made a serious mistake," it appears he won't be fired.
Much of the discussion around Lehrer centered on just how serious of a mistake he had made, and why it might have happened, Glucophage Dosage. Gawker's Hamilton Nolan argued that even if he's not cheating himself with his copying, he's cheating his employer, Rx free Glucophage, who's not paying him to recycle old material. Jack Shafer of Reuters made a similar point, but noted that certain types of republication are a pretty established part of journalistic practice. Poynter's Kelly McBride talked about how the practice cheats the audience.
As for why Lehrer might have done this, Gawker's Nolan concluded that Lehrer simply "doesn't know how to do journalism" and said that while he might consider himself just a purveyor of ideas, The New Yorker is very much a journalistic publication. Slate's Josh Levin posited that Lehrer's "big ideas" stock and trade isn't compatible with blogging Glucophage Dosage, , because while big ideas are rare and have to be wrung dry, blogging requires constant streams of fresh insight. At the Columbia Journalism Review, herbal Glucophage, Felix Salmon said "big ideas" blogging can indeed be done — by iterating ideas, using links as shorthand, riffing on what you're reading, and interacting with peers.
Others objected to the term "self-plagiarism" to describe what Lehrer did — the Washington Post's Erik Wemple, Reuters' Shafer, Glucophage photos, and the New York Times' Phil Corbett, via Poynter. And Poynter's Craig Silverman pointed out how catching plagiarists (or serial repeaters) has become something of a game in itself.
Debating the value of print in New Orleans: The aftermath of the New Orleans Times-Picayune's cuts continued this week, as the paper published another optimistic message to readers about its future, this one from its publisher, Ricky Mathews. Ryan Chittum of the Columbia Journalism Review criticized Mathews for not mentioning the paper's massive layoffs, and Poynter's Steve Myers reported on the efforts of readers and advertisers to provide for laid-off reporters and convince Advance to rethink its print cuts, Glucophage Dosage.
Poynter's Rick Edmonds agreed with those readers and former staffers, fast shipping Glucophage, breaking down the numbers and arguing that there isn't much of a business case for cutting print editions of the paper. Instead, he said, "The move only makes financial sense as the occasion for dumping many well-paid veterans and drastically slashing news investment" — which is how the paper appears to be using it.
The University of Colorado's Steve Outing defended the decision to cut print editions, arguing that an investment into mobile media by the TP could keep readers just as informed as with a seven-day print edition. Online Glucophage without a prescription, Poynter adjunct Jason Fry came down in the middle, saying that while he's not opposed to cutting print in general, New Orleans is the wrong place — and Advance's strategy the wrong way — to do it.
Glucophage Dosage, Two paywalls up, one down: News organizations (and newspapers in particular) continue to put up paywalls at a steady pace — this week, we got an announcement from one of Australia's largest newspaper companies, Fairfax Media, that it would put up a paywall and cut 1,900 jobs at its publications, two of which, the Sydney Morning Herald and The Age, will merge newsrooms. Poynter's Andrew Beaujon summarized the situation, and former Age editor Andrew Jaspan explained Fairfax's decline and sounded a warning regarding the concentration of Australian media in the hands of a few moguls.
Warren Buffett's longest-held newspaper, The Buffalo News, also announced plans for a paywall, Glucophage overnight. Beaujon has the details, and The New York Times' Christine Haughney examined the News for clues to Buffett's style of newspaper management. Elsewhere, however, the New York Post (a Rupert Murdoch paper) dropped the pay plan for its iPad version, and the Online Journalism Review's Robert Niles made the case against paywalls and urged newspapers to focus solely on the unique value they can provide.
A new set of news innovators: The Knight Foundation announced the winners of the first round of this year's Knight News Challenge, the first year of its new three-times-a-year incarnation, Glucophage Dosage. About Glucophage, Here are the six winners, all based on the theme of networks: Behavio, a collective mobile data-sharing service (Lab profile, Techcrunch profile); PeepolTV, a livestreamed video collection project; Recovers.org, a disaster recovery organization (Lab profile); Tor Project, an open-source anonymity-aiding initiative (Lab profile); Signalnoi.se, a tool to help newsrooms understand how information moves through social networks (Lab profile, Glucophage pharmacy, Journalism.co.uk profile); and Watchup, a video news iPad app (Lab profile).
Mathew Ingram of GigaOM saw in the winners the importance of mobile media, video, and large-scale data collection, while the Lab's Joshua Benton said he feels the overall quality of applications was up this year. Buy Glucophage without a prescription, The foundation also announced the creation of the Knight Prototype Fund, which is intended as a smaller-scale, quicker way of funding innovative news projects. The Lab's Justin Ellis profiled the fund, while the MIT Center for Civic Media published an interview with two of its principals.
Reading roundup: Here are the other stories folks in the news-tech world were talking about this week:
— The New York Times announced a partnership Glucophage Dosage, with BuzzFeed to collaborate on coverage of this year's political conventions, particularly through video. The Washington Post's Erik Wemple looked at what it means for the Times and BuzzFeed, and The Atlantic's Megan Garber said you can expect BuzzFeed's lolcattiest tendencies to be toned down.
— WikiLeaks' Julian Assange sought asylum in the Ecuadorian embassy in London as an attempt to avoid extradition to Sweden on sex crime accusations, Glucophage gel, ointment, cream, pill, spray, continuous-release, extended-release. Doing so was apparently a breach of his bail terms, but Salon's Glenn Greenwald defended Assange's right to seek asylum. Former WikiLeaks staffer James Ball looked at where things currently stand with the Assange drama.
— Information Architects' Oliver Reichenstein proposed a strikethrough "mark as error" function on Twitter as an alternative to deleting erroneous tweets, Glucophage Dosage. Poynter's Craig Silverman and GigaOM's Mathew Ingram voiced their support for the idea, and Journalism.co.uk asked editors for their thoughts on it. Twitter, Glucophage pictures, meanwhile, did introduce an option to view profiles without replies.
— In the most recent of several thoughtful pieces on how to improve journalism education that have been published lately, Howard Finberg advised j-schools to look to large-scale, online education to train tomorrow's journalists, and j-prof Jeff Jarvis sketched a few ideas for such a plan. J-prof Carrie Brown-Smith did counter, however, that j-schools' current skills education has value because an alarming number of students come in with such poor grasp of basic skills.
— Finally, two smart pieces to read this weekend: Here at the Lab, Jonathan Stray wrote about the inherent difficulties in designing filtering algorithms, and at Poynter, PolitiFact's Bill Adair urged journalists to supplant the news story as the basic form of journalism.
Similar posts: Purchase Synthroid. Synthroid Cost. Lipitor No Rx. Glucophage from canadian pharmacy. Where can i buy cheapest Flagyl online.
Trackbacks from: Glucophage Dosage. Glucophage Dosage. Glucophage Dosage. Order Glucophage no prescription. Glucophage dangers. No prescription Glucophage online.
[This review was originally posted at the Nieman Journalism Lab Buy Armour No Prescription, on April 13, 2012.]
Facebook scoops up Instagram: There were two billion-dollar deals in the tech world this week, and by far the bigger of the two was Facebook’s purchase of the photo-sharing app Instagram. Mathew Ingram of GigaOM has a good, quick roundup of initial reaction to the deal, but I’ll try to sort through each of the angles to the story, including what this means for Facebook, Instagram, and the tech world in general. Buy Armour online cod, The first big question was why Facebook bought Instagram, especially for so much money. The most common answer, voiced most persuasively by GigaOM’s Om Malik, was that Facebook felt threatened by Instagram’s ascendance in mobile photo sharing, one area in which Facebook has struggled. Business Insider’s Nicholas Carlson explained why Instagram does mobile photos so much better than Facebook, and Fortune’s Dan Primack suggested that Facebook panicked at all the money Instagram has raised recently, Armour maximum dosage.
The New York Times also characterized the deal as a big move by Facebook into mobile media, but there were other key aspects at work, too: Ingram said Instagram’s value lay in its network, and Wired’s Tim Carmody said what matters to Facebook is Instagram’s personal data, Buy Armour No Prescription. Rackspace’s Robert Scoble outlined some of the specifics of that data, and All Things Digital’s Lauren Goode focused on Instagram’s location data. New York’s Paul Ford said Facebook is attempting to buy Instagram’s sincerity: “Remember what the iPod was to Apple. That’s how Instagram might look to Facebook: an artfully designed product that does one thing perfectly.”
So what does this mean for Instagram. TechCrunch detailed the company’s rise, and the big concern was, Ordering Armour online, as CNN’s John Sutter put it, whether Facebook would “ruin” Instagram. Mashable’s Christina Warren urged Facebook Buy Armour No Prescription, to keep Instagram mobile-only and keep it separate from Facebook logins, and Jolie O’Dell of VentureBeat pointed out some of the good things Facebook’s developers could do for Instagram. TechCrunch noted that Facebook’s statement that it would keep Instagram as a separate product is a big departure from Facebook’s unified approach.
That concern over Facebook ruining Instagram indicates a certain revulsion for Facebook among Instagram users, something Om Malik took note of. Forbes’ John McQuaid said the sentiments reveal our uneasiness with the utility-like role tech giants like Facebook are playing in our new social world, and The Next Web’s Courtney Boyd Myers reminded Instagram users that the fact that they loved it so much was a big part of the reason it got bought in the first place.
The next question was for the tech industry as a whole: Does Instagram’s massive purchase price signal another tech market bubble, online Armour without a prescription. The Atlantic’s Rebecca Greenfield said it’s just time to accept the existence of a social media bubble, and the Guardian’s Charles Arthur said we may not be at the peak of inflated valuations, though also at the Guardian, Dan Gillmor said we could be near the end of the bubble, Buy Armour No Prescription. But Wired’s Andy Baio crunched the numbers and said Instagram wasn’t overvalued, and if anything, the tech market is rewarding efficiency. Forbes’ Robert Hof, meanwhile, looked at whether we’ll see more social media purchases soon, Armour schedule, coming up with some reasons for a slowdown.
Finally, Poynter’s Jeff Sonderman looked at some of the ways journalists have used Instagram, and Reuters’ Jack Shafer put the deal in the context of the larger cultural shift from voice to text to images. “So, Instagram is here,” he said. “What I want to know is: Where is it going to take us?”
Buy Armour No Prescription, Apple, publishers, Amazon, and ebooks’ future: The ebook industry absorbed a blow this week when the U.S. Department of Justice sued Apple and five of the largest book publishers for antitrust violations involving price-fixing for ebooks, cheap Armour. (Sixteen states also filed a lawsuit of their own.) Three of the publishers — Hachette, Simon & Schuster, and HarperCollins — immediately settled with the DOJ, and Wired’s Tim Carmody explained the terms of the settlement, which will undermine the model that the publishers created with Apple, though not kill it outright. Armour duration, Apple, Penguin, and Macmillan have decided not to settle, and the latter’s CEO issued a defiant letter in response to the suit.
PaidContent’s Laura Hazard Owen wrote a fantastic explanation of what the case is about, but in short, the issue centers on what’s called agency pricing, in which the publishers set book prices, Armour blogs, rather than the retailers, and the books must be at the same price across retailers. In 2010, Apple negotiated an agency pricing model with the big book publishers for the rollout of its iPad’s iBookstore, and the DOJ objected to that as price-fixing, Buy Armour No Prescription.
The Verge’s Nilay Patel dug through more of the details from the lawsuit of the alleged price-fixing process, particularly its response to Amazon’s perceived ebook dominance. At the same time, however, Buy generic Armour, as Peter Kafka of All Things Digital noted, Apple was allegedly considering a deal to divide and share rulership over online content with Amazon. A few people said the DOJ wasn’t likely to win the suit: Law prof Richard Epstein said the agency pricing arrangement has more social and consumer benefits than a classic collusion case, and CNET concluded that Apple should be able to win its case, too. Adam Thierer of the Technology Liberation Front put the strategy in the context of copyright challenges, coming out against the suit in the process. Buy Armour No Prescription, Also this week, we found out that several of the big publishers have refused to sign their annual contracts with Amazon, as Salon’s Alexander Zaitchik reported and Laura Hazard Owen explained. The Seattle Times has been running a critical series on Amazon, Armour gel, ointment, cream, pill, spray, continuous-release, extended-release, which, as the Los Angeles Times pointed out, includes some real concern about Amazon behaving anti-competitively by selling ebooks for too little.
Publishers have argued that that’s why agency pricing is necessary: It’s the best chance to keep Amazon from undercutting publishers and laying waste to the book industry. Web thinker Tim O’Reilly said the government should be watching Amazon more closely than the five companies it just sued, but Nate Hoffelder of The Digital Reader defended Amazon, Online buying Armour, arguing that it’s helping enable an entirely new publishing model in its stead.
Christopher Mims of Technology Review said it doesn’t matter if Amazon becomes a monopoly. And GigaOM’s Mathew Ingram also said Amazon’s practices have been good for consumers and good for innovation, unlike those of the publishers: “They seem to have spent most of their time dragging their feet and throwing up roadblocks to any kind of innovation … Their defense of the agency-pricing model feels like yet another attempt to stave off the forces of disruption, Buy Armour No Prescription. Why not try to adapt instead?”
Others had more personal stories: The legendary investigative reporter Seymour Hersh, longtime Philly television columnist Gail Shister, j-prof Dan Kennedy, and The Wrap’s Sharon Waxman, Buy Armour No Prescription. As Kennedy wrote: “I really do think there was a golden age of television news, and Wallace was right in the middle of it.”
— A few more takes on last week’s purchase of the Philadelphia Inquirer and Daily News by a group of local investors: The New York Times’ David Carr mused on the return of the newspaper baron, the American Journalism Review’s John Morton examined the recent spree of newspaper purchases in a downtime for the industry, Purchase Armour online no prescription, and Penn prof Victor Pickard argued for more systemic solutions to save papers like Philly’s.
— A couple of interesting pieces from the academic view of journalism: NYU’s Jay Rosen and MIT’s Ethan Zuckerman talked about trends in journalism at an MIT forum (summarized well by Matt Stempeck), and CUNY’s C.W. Anderson talked a bit about his research on data journalism to Tyler Dukes of Reporters’ Lab.
— The debate over the value of online commenting continues: Animal’s Joel Johnson proposed that comments are worth far less than publishers think, because they don’t draw many readers and don’t make money, but GigaOM’s Mathew Ingram countered that comments are an important check on online authority and that not allowing them tells readers to “go away.”
— News analyst Alan Mutter made the age-old argument that newspapers are failing in their digital efforts in a brief, potent piece decrying newspapers’ poor digital products and weak competitive response, and urging them to pool their efforts.
— Finally, Digital First Media’s Steve Buttry wrote a gracious but no-nonsense letter to newsroom curmudgeons defending digital journalism practices, then wrote about what he learned from its fallout, then addressed the role of news organizations themselves in enabling curmudgeonhood. The posts and comments are a good glimpse into the current state of newsroom culture and change.
Similar posts: Retin A Mg. Buy Diflucan No Prescription. Synthroid For Sale. Discount Glucophage. Get Synthroid. Tramadol pics.
Trackbacks from: Buy Armour No Prescription. Buy Armour No Prescription. Buy Armour No Prescription. Low dose Armour. Order Armour from United States pharmacy. Armour gel, ointment, cream, pill, spray, continuous-release, extended-release.